Meningococcal serogroup B infections: A search for a broadly protective vaccine

Expert Review of Vaccines

Volumn 2, Issue 5, 2003, Pages 673-681

  Vermont, Clementien L ^a,b   Van den Dobbelsteen, Germie P J M ^b  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b NETHERLANDS VACCINE INSTITUTE   (Netherlands)

Author keywords

Genomics; N. meningitidis serogroup B; Review; Vaccine candidates

Indexed keywords

ANTIGEN; APP VACCINE; AUTOTRANSPORTED SERINE PROTEASE A VACCINE; BACTERIAL ANTIGEN; BACTERIUM LIPOPOLYSACCHARIDE; CAPSULAR POLYSACCHARIDE VACCINE; EPITOPE; GENOME DERIVED NEISSERIA ANTIGEN 1870 VACCINE; GENOME DERIVED NEISSERIA ANTIGEN 2132 VACCINE; GENOME DERIVED NEISSERIA ANTIGEN 33 VACCINE; HAEMOPHILUS INFLUENZAE VACCINE; MENINGOCOCCUS VACCINE; NADA VACCINE; NEISSERIA MENINGITIDIS SURFACE PROTEIN A VACCINE; OUTER MEMBRANE PROTEIN; OUTER MEMBRANE VESICLE VACCINE; P2086; PORIN; PORIN A; RECOMBINANT PORIN VACCINE; TRANSFERRIN BINDING PROTEIN A VACCINE; TRANSFERRIN BINDING PROTEIN B VACCINE; UNCLASSIFIED DRUG;

BACTERIAL GENOME; BACTERIAL STRAIN; CLINICAL TRIAL; DRUG EFFICACY; GENE CONTROL; GENE EXPRESSION; GENE SEQUENCE; GENOMICS; HUMAN; IMMUNOGENICITY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; CLINICAL TRIALS; HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; VACCINES, SYNTHETIC;

EID: 0142058088     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.2.5.673     Document Type: Review

References (68)

1. Bjune G, Hoiby EA, Gronnesby JK et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338(8775), 1093-1096 (1991).
2. Tappero JW, Lagos R, Ballesteros AM et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 281(16), 1520-1527 (1999).
3. Boslego J, Garcia J, Cruz C et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 13(9), 821-829 (1995).
4. Cartwright K, Morris R, Rumke H et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 17(20-21), 2612-2619 (1999).
5. de Kleijn ED, de Groot R, Labadie J et al. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine 18(15), 1456-1466 (2000).
6. de Kleijn ED, de Groot R, Lafeber AB et al. Immunogenicity and safety of monovalent p 1. 7(h),4 meningococcal outer membrane vesicle vaccine in toddlers: comparison of two vaccination schedules and two vaccine formulations. Vaccine 19(9-10), 1141-1148 (2000).
7. de Kleijn ED, de Groot R, Lafeber AB et al. Prevention of meningococcal serogroup B infections in children: a protein-based vaccine induces immunologic memory. J. Infect. Dis. 184(1), 98-102 (2001).
8. Poolman J and Berthet FX. Alternative vaccine strategies to prevent serogroup B meningococcal diseases Vaccine 20 (Suppl. 1) S24-S26 (2001).
9. Haneberg B, Dalseg R, Wedege E et al. Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans Infect. Immun. 66(4), 1334-1341 (1998).
10. Oftung F, Naess LM, Wetzler LM et al. Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine Infect. Immun. 67(2), 921-927 (1999).
11. Haneberg B, Bakke H, Lie K et al. Improved formulation and immunization regime may be the key to effective nasal vaccines against meningococcal disease. 13th International Pathogenic Neisseria Conference, Oslo, Norway (2002).
12. Katial RK, Brandt BL, Moran EE, Marks S, Agnello V, Zollinger WD. Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine Infect. Immun. 70(2), 702-707 (2002).
13. Aase A, Naess LM, Sandin RH et al. Comparison of functional immune responses in humans after intranasal and intramuscular immunisations with outer membrane vesicle vaccines against group B meningococcal disease Vaccine 21(17-18), 2042-2051 (2003).
14. Steeghs L, Tommassen J, van Alphen L, van der Ley P. Modification of lipid A acylation pattern in Neiseria meningitidis: effects on endotoxic and adjuvant properties of LPS, and its interaction with Toll-like receptors TLR2 and 4. 13th International Pathogenic Neisseria Conference, Oslo, Norway (2002).
15. van der Ley P, Steeghs L, Hamstra HJ, ten Hove J, Zomer B, van Alphen L Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity Infect. Immun. 69(10), 5981-5990 (2001).
16. Kijek T, Fisseha M, Brandt B, Moran E, Chen P, Zollinger WD. Characterization of a genetically detoxified native outer membrane vesicle (NOMV) vaccine prepared for human use. 13th International Pathogenic Neisseria Conference, Oslo, Norway (2002).
17. Fisseha M, Chen P, Kijek TM, Brandt BL, Ionin B, Zollinger WD. Characterization of NOMV prepared from lpxL1 and lpxL2 mutants of Neisseria meningitidis with L3,7 and L8 lipooligosaccharide. Thirteenth International Pathogenic Neisseria Conference Oslo, Norway (2002).
18. Christodoulides M, Brooks JL, Rattue E and Heckels JE. Immunization with recombinant class 1 outer-membrane protein from Neisseria meningitidis: influence of liposomes and adjuvants on antibody avidity, recognition of native protein and the induction of a bactericidal immune response against meningococci Microbiology 144(Pt 11), 3027-3037 (1998).
19. Idanpaan-Heikkila I, Muttilainen S, Wahlstrom E et al. The antibody response to a prototype liposome vaccine containing Neisseria meningitidis outer membrane protein P1 produced in Bacillus subtilis Vaccine 13(16), 1501-1508 (1995).
20. Idanpaan-Heikkila I, Wahlstrom E, Muttilainen S et al. Immunization with meningococcal class 1 outer membrane protein produced in Bacillus subtilis and reconstituted in the presence of Zwittergent or Triton. X-100 Vaccine 14(9), 886-891 (1996).
21. Ward SJ, Scopes D, Christodoulides M, Clarke IN, Heckels JE. Expression of Neisseria meningitidis class 1 porin as a fusion protein in Escherichia coli: the influence of liposomes and adjuvants on the production of a bactericidal immune response. Microb. Pathog. 21(6), 499-512 (1996).
22. Humphries HE, Jolley K, Williams JN, Christodoulides M, Heckels JE. Vaccine strategies for recombinant meningococcal PorA protein. 13th International Pathogenic Neisseria Conference, Oslo, Norway (2002).
23. Wright JC, Williams JN, Christodoulides M, Heckels JE. Immunization with the recombinant PorB outer membrane protein induces a bactericidal immune response against Neisseria meningitidis. Infect. Immun. 70(8), 4028-4034 (2002).
24. Oomen CJ, Hoogerhout P, Bonvin AM et al. Immunogenicity of peptide-vaccine candidates predicted by molecular dynamics simulations. J. Mol. Biol. 328(5), 1083-1089 (2003).
25. Zollinger WD, Moran EE, Devi SJ, Frasch CE. Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines. Infect. Immun. 65(3), 1053-1060 (1997).
26. Fusco PC, Michon F, Tai JY, Blake MS. Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates. J. Infect. Dis. 175(2), 364-372 (1997).
27. Charalambous BM, Feavers IM. Mimotope vaccines. J. Med. Microbiol. 50(11), 937-939 (2001).
28. Granoff DM, Bartoloni A, Ricci S et al. Bactericidal mAb that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J. Immunol. 160(10), 5028-5036 (1998).
29. Moe GR, Granoff DM. Molecular mimetics of Neisseria meningitidis serogroup B polysaccharide. Int. Rev. Immunol. 20(2), 201-220 (2001).
30. Plested JS, Makepeace K, Jennings MP et al. Conservation and accessibility of an inner core lipopolysaccharide epitope of Neisseria meningitidis. Infect. Immun. 67(10), 5417-5426 (1999).
31. Mackinnon FG, Cox AD, Plested JS et al. Identification of a gene (lpt-3) required for the addition of phosphoethanolamine to the lipopolysaccharide inner core of Neisseria meningitidis and its role in mediating susceptibility to bactericidal killing and opsonophagocytosis. Mol. Microbiol. 43(4), 931-943 (2002).
32. Plested JS, Ferry BL, Coull PA et al. Functional opsonic activity of human serum antibodies to inner core lipopolysaccharide (galE) of serogroup B meningococci measured by flow cytometry Infect. Immun. 69(5), 3203-3213 (2001).
33. Plested JS, Harris SL, Wright JC et al. Highly conserved Neisseria meningitidis inner-core lipopolysaccharide epitope confers protection against experimental meningococcal bacteremia J. Infect. Dis. 187(8), 1223-1234 (2003).
34. Charalambous BM, Feavers IM. Peptide mimics elicit antibody responses against the outer-membrane lipooligosaccharide of group B neisseria meningitidis. FEMS Microbiol. Lett. 191(1), 45-50 (2000).
35. Brett PJ, Tiwana H, Feavers IM, Charalambous BM. Characterization of oligopeptides that cross-react with carbohydrate-specific antibodies by real time kinetics, in-solution competition enzyme-linked immunosorbent assay, and immunological analyses J. Biol. Chem. 277(23), 20468-20476 (2002).
36. Tiwana HCK, Feavers IM, Charalambous BM. Peptide conformational mimics elicit type 1 and type 2 T-cell responses in mice to meningococcal LPS. 13th International Pathogenic Neisseria Conference, Oslo, Norway (2002).
37. Clow KBP, Charalambous B, Feavers I. Identification of molecular mimics of MenB LOS as vaccine candidates. Thirteenth International Pathogenic Neisseria Conference, Oslo, Norway (2002).
38. Martin D, Cadieux N, Hamel J, Brodeur BR. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J. Exp. Med. 185(7), 1173-1183 (1997).
39. Moe GR, Tan S, Granoff D M. Differences in surface expression of NspA among Neisseria meningitidis group B strains Infect. Immun. 67(11), 5664-5675 (1999).
40. Moe GR, Zuno-Mitchell P, Lee SS, Lucas AH, Granoff DM. Functional activity of anti-Neisserial surface protein A mAb against strains of Neisseria meningitidis serogroup B. Infect. Immun. 69(6), 3762-3771 (2001).
41. Moe GR, Zuno-Mitchell P, Hammond SN, Granoff DM. Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains. Infect. Immun. 70(11), 6021-6031 (2002).
42. Lissolo L, Maitre-Wilmotte G, Dumas P, Mignon M, Danve B, Quentin-Millet MJ. Evaluation of transferrin-binding protein 2 within the transferrin-binding protein complex as a potential antigen for future meningococcal vaccines. Infect. Immun. 63(3), 884-890 (1995).
43. Rokbi B, Mignon M, Caugant DA and Quentin-Millet MJ. Heterogeneity of tbpB, the transferrin-binding protein B gene, among serogroup B Neisseria meningitidis strains of the ET-5 complex. Clin. Diagn. Lab. Immunol. 4(5), 522-529 (1997).
44. West D, Reddin K, Matheson M et al. Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection. Infect. Immun. 69(3), 1561-1567 (2001).
45. Funnell S, Gorringe A, Hudson M, Mignon M, Danve B, Lissolo L Assessment of the potential of TbpA+TbpB vaccines to protect against experimental meningococcal infection. 13th International Pathogenic Neisseria Conference, Oslo, Norway (2002).
46. Gold R, Goldschneider I, Lepow ML, Draper TF, Randolph M. Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. J. Infect. Dis. 137(2), 112-21 (1978).
47. Oliver KJ, Reddin KM, Bracegirdle P et al. Neisseria lactamica protects against experimental meningococcal infection. Infect. Immun. 70(7), 3621-3626 (2002).
48. O'Dwyer CA, Reddin KM, Martin D et al. Meningococcal NspA expressed in commensal Neisseria - a vaccine paradigm. 13th International Pathogenic Neisseria Conference, Oslo, Norway (2002).
49. Tettelin H, Saunders NJ, Heidelberg J et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58 Science 287(5459), 1809-1815 (2000). The first paper describing possible new vaccine candidates derived from the meningococcal genome sequence by analyzing open reading frames that potentially code for surface-exposed or exported proteins.
50. Parkhill J, Achtman M, James KD et al. Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491. Nature 404(6777), 502-506 (2000).
51. Pizza M, Scarlato V, Masignani V et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287(5459), 1816-1820 (2000).
52. Jennings GT, Savino S, Marchetti E et al. GNA33 from Neisseria meningitidis serogroup B encodes a membrane-bound lyric transglycosylase (MltA). Eur. J. Biochem. 269(15), 3722-3731 (2002).
53. Granoff DM, Moe GR, Giuliani MM et al. A novel mimetic antigen eliciting protective antibody to Neisseria meningitidis. J. Immunol. 167(11), 6487-6496 (2001).
54. Welsch JA, Moe GR, Granoff DM. Genome-derived antigen (GNA) 2132 elicits protective serum antibodies to groups B and C Neisseria menigitidis strains. Thirteenth International Pathogenic Neisseria Conference, Oslo, Norway (2002).
55. Comanducci M, Bambini S, Brunelli B et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J. Exp. Med. 195(11), 1445-1454 (2002).
56. Giuliani MM, Santini L, Brunelli B, Pizza M, Rappuoli R. A novel antigen of Neisseria meningitidis as target for bactericidal antibodies. Thirteenth International Pathogenic Neisseria Conference, Oslo, Norway (2002).
57. Masignani V, Comanducci M, Giuliani MM et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med. 197(6), 789-799 (2003).
58. This is a paper on an interesting new vaccine candidate, discovered from the meningococcal genome sequence project, lipoprotein GNA1870; which is present on all tested meningococcal strains.
59. Bernfield L, Fletcher L, Howell A, Farley J et al. Identification of a novel vaccine candidate for group B Neisseria meningitidis. Thirteenth International Pathogenic Neisseria Conference, Oslo, Norway (2002).
60. Hadi HA, Wooldridge KG, Robinson K, Ala'Aldeen DA. Identification and characterization of App: an immunogenic autotransporter protein of Neisseria meningitidis. Mol. Microbiol. 41(3), 611-623 (2001).
61. van Ulsen P, van Alphen L, Hopman CT, van der Ende A, Tommassen J. In vivo expression of Neisseria meningitidis proteins homologous to the Haemophilus influenzae Hap and Hia autotransporters. FEMS Immunol. Med. Microbiol. 32(1), 53-64 (2001).
62. Turner DP, Wooldridge KG, Ala'Aldeen DA. Autotransported serine protease A of Neisseria meningitidis: an immunogenic, surface-exposed outer membrane, and secreted protein. Infect. Immun. 70(8), 4447-4461 (2002).
63. Dietrich G, Kurz S, Hubner C et al. Transcriptome analysis of Neisseria meningitidis during infection. J. Bacteriol. 185(1), 155-164 (2003).
64. Kurz S, Hubner C, Aepinus C et al. Transcriptome-based antigen identification for Neisseria meningitidis. Vaccine 21(7-8), 768-775 (2003).
65. Grifantini R, Bartolini E, Muzzi A et al. Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nat. Biotechnol. 20(9), 914-921 (2002). The first paper describing the use of microarray techniques in identifying new vaccine candidates upon interaction with human epithelial cells.
66. Sun YH, Bakshi S, Chalmers R, Tang CM. Functional genomics of Neisseria meningitidis pathogenesis. Nat. Med. 6(11), 1269-1273 (2000). The only paper so far describing signature-tagged mutagenesis as a method for identification of meningococcal pathogenesis-associated genes.
67. Pelici V, Floquet S, Mouze C, Geoffroy MC, Nassif X. Use of a genome-wide collection of Neisseria meningitidis mutants for an in depth analysis of the meningococcal genome. 13th International Pathogenic Neisseria Conference, Oslo, Norway (2002).
68. Suker J, Feavers IM. Prospects offered by genome studies for combating meningococcal disease by vaccination. Pharmacogenomics 2(3), 273-283 (2001).